Ascletis completes subject enrolment in Phase II ASC3 trial
Ascletis Pharma has completed subject enrolment in its 13-week US Phase II study of ASC30, an oral small molecule GLP-1 …
Post
-
-
Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML
Kyowa Kirin and Kura Oncology have started a Japanese Phase II registrational study of oral menin inhibitor ziftomenib in adult …
-
The slow march of clinical biomarkers to become surrogate endpoints
Clinicians have often pushed for certain biomarkers to move from serving a purely informative role in clinical trials to becoming …
-
AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, during a poster session, Axsome Therapeutics presented results …
-
Africa-Europe partnership delivers first clinical trial for malaria in early pregnancy
A partnership between Europe and Africa has seen the initiation of a clinical trial of an anti-malaria drug in early …
-
Africa-Europe partnership delivers first clinical trial for malaria in early pregnancy
A partnership between Europe and Africa has seen the initiation of a clinical trial of an anti-malaria drug in early …
-
AAN 2026: Solengepras demonstrates emerging benefit in early Parkinson’s disease
At the American Academy of Neurology (AAN) 2026 annual conference, Cerevance reported findings from the Phase II ASCEND (NCT06006247) trial …
-
AI-driven cardiometabolic clinical trial recruitment and retention
For sponsors running cardiometabolic programs, early clinical development often hinges on one question: can a site deliver predictable recruitment, high …
-
Epitopea receives MHRA and REC approvals for OVACT ovarian cancer trial
Epitopea has secured approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and the Regional Ethics Committee (REC) in …
-
CatalYm doses first patient in Phase II/III VINCIT trial
CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its …
-
ESCMID Global 2026: Olorofim targets invasive Aspergillus in hematology patients
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference in Munich, Germany, data on F2G’s …
-
AAN 2026: BlueRock reports positive safety data for bemdaneprocel in Parkinson’s
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, BlueRock Therapeutics, a wholly owned, independently operated subsidiary …
-
Non-animal testing goes mainstream, but success hinges on smart use
As new approach methodologies (NAMs) burst onto the scene amid the wider shift away from animal testing, biotech and pharma …
-
500,000 patients’ data for sale online after UK Biobank breach
Last week, data from 500,000 participants of UK Biobank’s database were made available for sale online following a breach, the …
-
J&J’s Imaavy shows two-year benefit in gMG
Johnson & Johnson’s (J&J’s) Imaavy (nipocalimab-aahu) has shown continued benefit for two years in patients with generalised myasthenia gravis (gMG) Patients …
